Search company, investor...

Predict your next investment

Mission BioCapital company logo
Venture Capital
missionbiocapital.com

Investments

43

Portfolio Exits

6

Funds

1

About Mission BioCapital

Mission BioCapital is an early-stage life science venture capital firm. Mission BioCapital brings together two life science venture firms: BioInnovation Capital and Mission Bay Capital. It was founded in 2015 and is based inSan Francisco, California.

Headquarters Location

953 Indiana Street

San Francisco, California, 94107,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Mission BioCapital News

Shape Therapeutics Secures $112 Million in Series B

Jul 21, 2023

Seattle, Washington, UNITED STATES SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. “We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinson’s disease, Alzheimer’s disease, alpha-1 antitrypsin deficiency and Rett syndrome,” said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. “We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.” ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. ShapeTX’s vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. “We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry,” said Min Cui, PhD, Founder and Managing Director at Decheng Capital. “We have been incredibly impressed with ShapeTX’s technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines.” About Shape Therapeutics Inc. Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Shape Life! shapetx.com Business Contact:

Mission BioCapital Investments

43 Investments

Mission BioCapital has made 43 investments. Their latest investment was in Mediar Therapeutics as part of their Series A - II on March 15, 2023.

CBI Logo

Mission BioCapital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/15/2023

Series A - II

Mediar Therapeutics

$85M

No

6

3/9/2023

Series B

QurAlis

$88M

No

10

1/11/2023

Series B - II

Vaxess Technologies

$10M

No

1

12/2/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/14/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/15/2023

3/9/2023

1/11/2023

12/2/2022

11/14/2022

Round

Series A - II

Series B

Series B - II

Series A

Seed VC

Company

Mediar Therapeutics

QurAlis

Vaxess Technologies

Subscribe to see more

Subscribe to see more

Amount

$85M

$88M

$10M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

10

1

10

10

Mission BioCapital Portfolio Exits

6 Portfolio Exits

Mission BioCapital has 6 portfolio exits. Their latest portfolio exit was Cereius on June 22, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2023

Acquired

$99M

3

8/31/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/14/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/9/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/29/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/22/2023

8/31/2021

6/14/2021

4/9/2021

10/29/2020

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Mission BioCapital Fund History

1 Fund History

Mission BioCapital has 1 fund, including Mission BioCapital V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/4/2021

Mission BioCapital V

$275M

2

Closing Date

11/4/2021

Fund

Mission BioCapital V

Fund Type

Status

Amount

$275M

Sources

2

Mission BioCapital Team

7 Team Members

Mission BioCapital has 7 team members, including current Founder, General Partner, Johannes Fruehauf.

Name

Work History

Title

Status

Johannes Fruehauf

Founder, General Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Johannes Fruehauf

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, General Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.